Shocking new research exposes how medical cannabis fails 58% of chronic pain patients within a year, leaving millions—especially seniors—suffering without real relief amid federal neglect of pain research.
Story Highlights
- 57.9% of chronic pain patients quit medical cannabis within 12 months, with 44.7% stopping in the first 3 months.
- Older adults over 65 show highest discontinuation rates, mean age 71.5 among quitters.
- Federal HHS budget for 2026 omits all dedicated pain research funding despite 60 million Americans affected.
- NIH dismantled key pain office in 2025, fragmenting research critical for non-opioid solutions.
- UT Health San Antonio secures rare NIH grant for targeted non-opioid chronic pain treatments.
Rothman Study Reveals Cannabis Shortfall
The Rothman Institute Foundation for Opioid Research & Education published a landmark study in PLOS One in August 2025. Researchers tracked orthopedic chronic pain patients prescribed medical cannabis. Results showed 57.9% discontinued treatment within one year. Nearly half, 44.7%, quit within three months. Age emerged as the sole statistically significant predictor of discontinuation. Older patients, averaging 71.5 years among quitters versus 64.5 for continuers, faced highest dropout rates. This first comprehensive one-year certification analysis challenges cannabis hype as an opioid alternative.
Federal Neglect Hits Pain Research Hard
HHS Secretary Robert F. Kennedy Jr. oversaw the April 2025 dismantling of NIH’s Office of Pain Policy and Partnerships, firing the entire staff. The proposed 2026 HHS budget of $94.7 billion excludes any dedicated pain research or treatment funding. Chronic pain impacts 60 million Americans, more than diabetes, heart disease, and cancer combined. It costs the healthcare system $77 billion yearly. Dr. Juan Hincapie-Castillo of UNC Chapel Hill warns pain research now has “no home at all” in NIH’s 27 fragmented institutes. This shift prioritizes fiscal restraint over patient needs.
Expert Insights Demand Better Alternatives
Dr. Asif M. Ilyas of Rothman Institute states medical cannabis fails expectations for many despite adoption enthusiasm. Lead author Dr. Mohammad Khak notes factors like cost, access to quality product, and perceived benefits likely drive quits, not pain type or health status. Gaps persist in data on formulations, dosages, side effects, and satisfaction. Authors urge multi-center studies. Meanwhile, UT Health San Antonio’s February 2026 NIH grant renewal targets muscle-joint chronic pain with novel non-opioid therapies. Dr. Akopian emphasizes resolving pain mechanisms, not masking symptoms.
Chronic pain shortens lifespans by up to 10 years via reduced activity and health decline. Opioids risk addiction; cannabis shows poor retention. Older adults and low-income patients suffer most from limited options and inconsistent quality. Medical cannabis industry credibility wanes as patients abandon treatment. Policymakers must restore focused funding to develop evidence-based solutions.
"If Your Chronic Pain Feels Dismissed, This New Research Is For You" (Mindbodygreen) on SmartNews: https://t.co/oxUVfYb2hU #SmartNews
— hardknoxfirst 🇺🇦 (@hardknoxfirst) February 26, 2026
Impacts on Patients and Policy
Seniors face recalibrated expectations for cannabis therapy. Physicians adjust protocols based on age patterns. Unresolved pain perpetuates public health burdens and costs. Opioid-sensitive groups seek viable alternatives amid research shortfalls. Federal cuts slow non-opioid innovation despite UT grant progress. Cannabis advocates cite study limits, but data gaps underscore urgency for rigorous trials.
Sources:
Majority of chronic pain patients found to discontinue medical cannabis within one year
Pain Research and Treatment Missing from 2026 HHS Budget
NIH layoffs include entire division devoted to chronic pain
